Ocular Symptoms
1 Vision Changes
Clinical Presentation.
- Blurred vision or difficulty focusing
- Double vision (diplopia)
- Visual distortions or “floaters”
- Dry eyes
- Eye pain or pressure
- Difficulty with accommodation (switching focus between near and far)
- Progressive presbyopia (age-related vision decline occurring early)
- Energy-dependent vision quality (better on high-energy days, worse on low-energy days)
- Convergence insufficiency and difficulty sustaining reading (Johansson et al. 2022)
- New-onset misalignment of the eyes (adult-onset strabismus) — rare and, when present, points to involvement of the nerves controlling the eye muscles (Moustardas et al. 2026)
Mechanism. Vision problems reflect ciliary muscle fatigue (accommodation requires sustained ATP for muscle contraction), autonomic dysfunction affecting pupil control, and energy-dependent visual processing in the brain. Post-infectious cohorts make these mechanisms concrete: in patients with persistent ocular symptoms after mild COVID-19, standard eye exams are normal, yet specialised testing reveals weakened autonomic pupillary reflexes (pupils admitting excess light, explaining light sensitivity), corneal small-nerve degeneration, and — in a minority — adult-onset strabismus from oculomotor nerve involvement (Moustardas et al. 2026). Task-evoked pupillary dynamics are measurably blunted in post-COVID syndrome (Smit et al. 2026), and dry-eye prevalence is elevated after COVID-19 (Naseri et al. 2025). The dry-eye (sicca) symptom itself has several candidate mechanisms in ME/CFS — autonomic (parasympathetic) withdrawal from the tear glands, anticholinergic medication effects, and possible subclinical autoimmune overlap with Sjögren’s syndrome — discussed and contrasted in Functional Lacrimal Denervation — a Candidate Non-Autoimmune Route to Sicca in ME/CFS and Shared M3 Muscarinic Autoantibodies Link Sjögren’s Syndrome Sicca and ME/CFS Autonomic Dysfunction, with the medication and dry-eye confounds weighed in Why the Ocular-Surface Signal in ME/CFS May Be an Artefact, Not a Window. Whether the same profile characterises ME/CFS specifically remains untested (see Post-COVID Ocular Syndrome Directly Confirms the Dysautonomia–Neuropathy–Immune Triad in an Accessible Tissue).
(Origin: brainstorm.) (Certainty: 0.25.) If ME/CFS photophobia arises partly from impaired autonomic pupil control admitting excess light (Moustardas et al. 2026), reducing the incident light load may ease symptoms independent of the underlying nerve pathology. FL-41 tint (a rose-coloured filter attenuating ~480 nm blue-green light) has controlled-trial support for photophobia in migraine and blepharospasm and is inexpensive, non-pharmacological, and free of systemic side effects — a rare combination for severe and bedbound patients who tolerate few interventions.
Falsifiable prediction: In ME/CFS patients with self-reported photophobia, FL-41 lenses will reduce photophobia scores versus clear or grey lenses of equal luminous transmittance in a crossover trial. Falsified if benefit does not exceed a neutral-density control (i.e., the effect is pure dimming, not spectral).
Limitations: Photophobia mechanism in ME/CFS may differ from migraine (autonomic/pupillary vs trigeminovascular); benefit is symptomatic, not disease-modifying; no ME/CFS-specific trial exists. Over-tinting risks dark adaptation and social/functional cost.
Consequence: A cheap pair of tinted glasses may take the edge off light sensitivity for some patients while carrying essentially no risk — worth an empirical trial, but not a treatment for the underlying disease.